Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis

(2016) Yi-Chia Lee et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Treatment ofHelicobacter pyloriinfection: Where are we now?

(2016) Jyh-Ming Liou et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication ofHelicobacter pyloriin the community and hospital populations: a randomised trial

(2015) Jyh-Ming Liou et al.   GUT

Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis

(2015) Manuel A Valenzuela   WORLD JOURNAL OF GASTROENTEROLOGY

The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study

(2015) Jyh-Ming Liou et al.   PLoS One

Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication

(2014) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Changes in the first lineHelicobacter pylorieradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (TokyoHelicobacter pyloristudy group)

(2014) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Reactive Oxygen Species-Induced Autophagic Degradation of Helicobacter pylori CagA Is Specifically Suppressed in Cancer Stem-like Cells

(2012) Hitoshi Tsugawa et al.   Cell Host & Microbe

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

(2012) Catherine de Martel et al.   LANCET ONCOLOGY

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology